Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sankyo to Split Off Most Indirect Divisions
November 22, 2004
- Asahi Kasei Pharma: Sales Down 2.1% at \52.7 Bil.
November 22, 2004
- MEDICAL DEVICE NEWS IN BRIEF
November 22, 2004
- Changing "Mevalotin Sankyo" into "CV Drug Sankyo": Mr Shoda
November 22, 2004
- Dainippon Preparing for Recovery in FY2005: Mr Miyatake
November 22, 2004
- Semiannual Business Results
November 22, 2004
- Sankyo: Tough Competition in Mevalotin Hurts Drug Division Sales
November 22, 2004
- Taiyo: Sales Up 11% to \12.4 Bil.
November 22, 2004
- TOPICS 2 articles
November 22, 2004
- Semiannual Business Results
November 22, 2004
- Towa: Consolidated Sales of \12.0 Bil. Posted
November 22, 2004
- BULLETIN
November 22, 2004
- Meet the Leaders (38)
November 22, 2004
- Towa Lowers Sales Forecast for Products Listed in July by 50%
November 22, 2004
- WORLD NEWS IN BRIEF
November 22, 2004
- CAGR of 7% in Sales, 15% in Operating Profits over 3 Years Targeted: Astellas
November 22, 2004
- Kenei: Net Profits Decline Due to Contract Mfg Slump
November 22, 2004
- Sales Goal of Spiriva Set for \20 Bil.: NBI, Pfizer
November 22, 2004
- Shionogi to Make All-out Effort to Boost Sales of Crestor
November 22, 2004
- FPMAJ, JPMA Submit Petition on FY2005 Budget, Tax Reform
November 22, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…